StockNews.com Initiates Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

Equities researchers at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report released on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

Shares of TCON opened at $0.06 on Wednesday. The company’s fifty day moving average price is $0.09 and its 200-day moving average price is $0.62. TRACON Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $14.75. The firm has a market capitalization of $197,780.00, a PE ratio of 0.02 and a beta of 1.43.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The business had revenue of $0.06 million during the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.